Trade Summary

3 days ago, Tyagarajan Seshu, serving as Chief Technology Officer at Candel Therapeutics, Inc. (CADL), sold 7,000 shares at $10.02 per share, for a total transaction value of $70,151.20. Following this transaction, Tyagarajan Seshu now holds 83,865 shares of CADL.

This sale represents a 7.70% decrease in Tyagarajan Seshu's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 29, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 1, 2026 at 4:22 PM ET, 2 days after the trade was made.

Candel Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.